Scarica l'app Stockscreener
20.84
4.15%
0.83
Precedente Chiudi:
$20.01
Aprire:
$20.3
Volume 24 ore:
278.55K
Relative Volume:
0.20
Capitalizzazione di mercato:
$2.49B
Reddito:
$22.57M
Utile/perdita netta:
$-212.73M
Rapporto P/E:
-11.55
EPS:
-1.8045
Flusso di cassa netto:
$-142.19M
1 W Prestazione:
-1.98%
1M Prestazione:
-1.51%
6M Prestazione:
-38.72%
1 anno Prestazione:
-48.48%
Intervallo 1D:
$20.21
$20.98
Intervallo di 1 settimana:
$19.58
$21.97
Portata 52W:
$19.58
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Nome
Newamsterdam Pharma Company Nv
Settore
Industria
Telefono
35 206 2971
Indirizzo
GOOIMEER 2-35, NARRDEN
Compare NAMS vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
20.84 | 2.49B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
510.88 | 129.49B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.79 | 94.53B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
805.67 | 82.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.42 | 53.29B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-07-21 | Iniziato | BMO Capital Markets | Outperform |
| 2026-03-18 | Iniziato | Truist | Buy |
| 2025-10-20 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-25 | Iniziato | Wells Fargo | Overweight |
| 2025-07-17 | Iniziato | Goldman | Neutral |
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2025-06-10 | Iniziato | Stifel | Buy |
| 2025-06-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-15 | Iniziato | TD Cowen | Buy |
| 2024-03-14 | Iniziato | Scotiabank | Sector Outperform |
| 2024-01-18 | Iniziato | Guggenheim | Buy |
| 2024-01-16 | Iniziato | Piper Sandler | Overweight |
| 2023-10-30 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Newamsterdam Pharma Company Nv Borsa (NAMS) Ultime notizie
After exercising options, Futurum sold 50,246 NewAmsterdam Pharma (NAMS) shares at an average $25.03. - stocktitan.net
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
Seven new hires receive stock options to buy NewAmsterdam shares at $24.16 each. - stocktitan.net
Five Frazier funds detail their NewAmsterdam (NASDAQ: NAMS) positions - Stock Titan
NewAmsterdam Pharma (NasdaqGM:NAMS) Stock Forecast & Analyst Predictions - Simply Wall Street
NewAmsterdam Pharma (NAMS) CEO adds to stake with fresh share purchase - Stock Titan
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test - Investing.com
NewAmsterdam Pharma at Cantor conference: obicetrapib nears key test By Investing.com - Investing.com UK
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma at Wells Fargo conference: obicetrapib push By Investing.com - Investing.com UK
NewAmsterdam Pharma (NAMS) director sells shares to cover tax bill - Stock Titan
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - investing.com
Newamsterdam Pharma stock hits 52-week low at 23.02 USD - Investing.com India
Newamsterdam Pharma stock hits 52-week low at 23.02 USD By Investing.com - Investing.com UK
NewAmsterdam Pharma: Potential Coupled With Uncertainty (NASDAQ:NAMS) - Seeking Alpha
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com South Africa
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com India
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session - Benzinga
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure By Investing.com - Investing.com UK
Stifel reiterates Buy on NewAmsterdam Pharma stock after trial failure - Investing.com
Price to earnings forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Why (NAMSW) Price Action Is Critical for Tactical Trading - Stock Traders Daily
NewAmsterdam Pharma Company N.V. - Reuters
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
NewAmsterdam Pharma VP Robert Gunning Granted 3,200 RSUs and 14,000 Stock Options - kalkinemedia.com
NewAmsterdam Pharma (NAMS) awards 14,000 options and 3,200 RSUs to controller - Stock Titan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NAMS Q2 2026 Earnings: Quarterly Net Loss Widens Slightly on R&D InvestmentPre-Earnings Setup - vinanet.vn
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
New hires receive options to buy NewAmsterdam shares at $24.92. Some awards vest over four years. - Stock Titan
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - The Manila Times
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September - GlobeNewswire
Precision Trading with Newamsterdam Pharma Company N.v. (NAMS) Risk Zones - Stock Traders Daily
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Barchart.com
NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - kalkine.ca
NewAmsterdam Pharma Company N.V. Warrant (NASDAQ: NAMSW) Stock Price, News & Analysis - Kalkine
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate plans Nasdaq share sale over 90 days - Stock Titan
NewAmsterdam Pharma (NASDAQ: NAMS) affiliate readies Nasdaq share sale - Stock Titan
NewAmsterdam (NAMSW) Shares: Moves 3.19% Higher to $16.51; Level Watch: the Price Remains Bounded by the Supplied Support and Resistance in the Latest ReadingFactor Momentum - vinanet.vn
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayMargin Expansion Trends - dars.gov.et
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Miss Alert - dars.gov.et
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayDownward Estimate Revision - dars.gov.et
NewAmsterdam (NAMS) Earnings Update: The EPS Result Is Below Expectation in Latest Trading; Investor Response: Shares Close 4.70% Higher on the DayEarnings Acceleration Picks - vinanet.vn
NewAmsterdam (NAMSW) Shares: Shows Minimal Net Change at $16.00 in Latest Trading; Trading Range: Support at $15.20 and Resistance at $16.80 Frame the Range in the Latest SessionSingle Stock ETF - vinanet.vn
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Newamsterdam Pharma Company Nv Azioni (NAMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Newamsterdam Pharma Company Nv Azioni (NAMS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Davidson Michael H. | Chief Executive Officer |
Sep 14 '26 |
Buy |
22.65 |
10,000 |
226,500 |
792,923 |
| Smither John W | Director |
Sep 04 '26 |
Sale |
25.32 |
1,600 |
40,512 |
8,760 |
| Kastelein Johannes Jacob Piete | Chief Scientific Officer |
Aug 24 '26 |
Sale |
26.91 |
125,000 |
3,363,750 |
69,302 |
| Kastelein Johannes Jacob Piete | Affiliate |
Aug 24 '26 |
Proposed Sale |
27.87 |
125,000 |
3,483,750 |
0 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jul 20 '26 |
Option Exercise |
11.34 |
105,000 |
1,191,100 |
129,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jul 20 '26 |
Sale |
30.34 |
105,000 |
3,185,656 |
24,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jun 22 '26 |
Option Exercise |
11.28 |
40,000 |
451,000 |
64,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
Jun 22 '26 |
Sale |
30.20 |
40,000 |
1,208,159 |
24,353 |
| Kooij Louise Frederika | Chief Accounting Officer |
May 26 '26 |
Sale |
35.69 |
65,000 |
2,319,850 |
24,353 |
| Louise Kooij | Officer |
May 26 '26 |
Proposed Sale |
35.44 |
210,000 |
7,442,400 |
0 |
1.86%
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):